-
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
Thursday, November 1, 2018 - 9:26am | 1612Read More...October was a volatile month for the markets, and biotech stocks were no exception. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) had slipped about 17 percent in the period. This compares to S&P 500's 7 percent retreat. As we enter the last leg of the year, here are a few PDUFA...
-
Mark Cuban Says 'It's Time To Bring Drug Pricing Under Control,' Cites Report From Harvard Business Review
Monday, July 11, 2016 - 2:28pm | 448Read More...Mark Cuban, the famed billionaire entrepreneur and owner of the NBA's Dallas Maverick, tweeted his support for drug pricing controls on Monday. He stated, "Empathy arbitrage can not be a pricing strategy." In a response to a follower, Cuban added "innovation won't decline" when companies lose out...
-
Catalyst Pharmaceuticals Crashes 50% Following 'Refusal To File' Letter From FDA
Wednesday, February 17, 2016 - 11:16am | 256Read More...Shares of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) lost nearly half of its value Wednesday morning after the company disclosed it received a "Refusal to File" letter from the U.S. Food and Drug Administration. The "Refusal to File" letter was sent to Catalyst...
